Качество жизни больных нестабильной бронхиальной астмой: влияние комбинированной терапии

The aim of this study was to evaluate influence of combined therapy with Seretid-Multidisk on quality of life (QoL) in patients with brittle and moderate asthma (BA). The study involved 33 patients: 21 patients had moderate BA (the 1 st group) and 12 ones had brittle BA (the 2 nd group) who received 1500 meg of beclomethazone dipropionate daily or another inhaled steriod in the equal dose 2.5 months at least and kept the daily bronchial lability more than 40% for at least 50% of the latter 75-day period. The basic therapy included Seretid-Multidisk 50/250: 1 inhaled dose twice a day in the 1 st group and 2 inhaled doses twice a day in the 2 nd group. The combined therapy with Seretid-Multidisk abolished a difference between QoL in moderate and brittle asthmatic patients. Seretid-Multidisk effected to the psycho-emotional and social fields in the brittle BA patients more than to those in the moderate BA patients. The combined therapy improved the QoL in BA patients in 3 days on the treatment keeping the effect up to 3 months.